Considerations for Successful Scale-Up To Tox
Batches And Phase-Api (Bulk Drugsubstance)
Volume 1 - Issue 3
Krishna Sarma Pathy*
-
Author Information
Open or Close
- Head /QC/QAIPL research centre, Department of Pharmacy, India
*Corresponding author:
Krishnasarma pathy, Head /QC/QAIPL research centre, Department of Pharmacy, India,
Email:
drkrishnasarmapathy@yahoo.in
Received: August 17, 2018; Published: August 28, 2018
DOI: 10.32474/LOJMS.2018.01.000112
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Practical Considerations in Pharmaceutical Production Scale-Up- This paper is meant to provide a high-level overview of
the steps required to prepare the bulk drug substance API. From first-in-human and through each of the clinical trial stages and
into commercialization, scale-up of formulation design is a natural part of pharmaceutical development. At each stage of process
development, the batch size increases, from laboratory-scale batches that may be quite small to support preclinical and early
clinical stages, to pilot batches that are used in process development, and finally to the production-scale batches needed to support
commercialization.
Abstract|
Introduction|
Conclusion|
References|